Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × GV1001 peptide × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Tumor-Agnostic 1 Thoracic 1 Dermatologic 1

Conditions

Inoperable Stage III Non-small Cell Lung Cancer 1

Interventions

Carboplatin 1016 Cisplatin 789 Pemetrexed 733 pembrolizumab 535 Paclitaxel 524 Docetaxel 479 Gemcitabine 366 Radiotherapy 337 Erlotinib Hydrochloride 334 Bevacizumab 292 Nivolumab 283 Etoposide 263 durvalumab 235 Drug Therapy 205 osimertinib 190 atezolizumab 182 Radiosurgery 163 Gefitinib 156 Vinorelbine 130 Magnetic Resonance Spectroscopy 110 130-nm albumin-bound paclitaxel 109 Ipilimumab 102 Cetuximab 98 Topotecan 91 Cyclophosphamide 91 tislelizumab 88 Taxes 87 Irinotecan 84 anlotinib 83 Albumin-Bound Paclitaxel 82

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01579188 2012-04-19

LucaVax

Kael-GemVax Co., Ltd.

Phase 3 Unknown

Inoperable Stage III Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡